Janis M Taube

List of Publications by Citations

142 papers	40,035 citations	59 h-index	155 g-index
155 ext. papers	48,845 ext. citations	12.6 avg, IF	6.98 L-index

#	Paper	IF	Citations
142	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New England Journal of Medicine*, **2012**, 366, 2443-54	59.2	8684
141	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *New England Journal of Medicine*, **2015**, 372, 2509-20	59.2	5560
140	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*, **2017**, 357, 409-413	33.3	3274
139	Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. *Journal of Clinical Oncology* , **2010**, 28, 3167-75	2.2	2163
138	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *Journal of Clinical Oncology*, **2014**, 32, 1020-30	2.2	1684
137	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. *Clinical Cancer Research*, **2014**, 20, 5064-74	12.9	1661
136	Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Science Translational Medicine*, **2012** , 4, 127ra37	17.5	1562
135	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nature Reviews Cancer*, **2016**, 16, 275-87	31.3	1444
134	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *New England Journal of Medicine*, **2016**, 375, 1749-1755	59.2	1100
133	The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discovery*, **2015**, 5, 43-51	24.4	890
132	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. *New England Journal of Medicine*, **2018**, 378, 1976-1986	59.2	865
131	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. *New England Journal of Medicine*, **2016**, 374, 2542-52	59.2	828
130	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. *Cancer Research*, **2013**, 73, 1733-41	10.1	564
129	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. *JAMA Oncology*, **2017**, 3, 1051-1058	13.4	491
128	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. *Cancer Research*, **2016**, 76, 227-38	10.1	423
127	Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. *Clinical Cancer Research*, **2013**, 19, 462-8	12.9	407
126	PD-1/PD-L1 inhibitors. *Current Opinion in Pharmacology*, **2015**, 23, 32-8	5.1	358

125	Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. *American Journal of Pathology*, **2011**, 179, 1608-15	5.8	328
124	Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. *Oncotarget*, **2013**, 4, 2067-79	3.3	285
123	PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. *Cancer Immunology Research*, **2013**, 1, 54-63	12.5	277
122	Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. *Gut*, **2017**, 66, 794-801	19.2	274
121	Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. *American Journal of Surgical Pathology*, **2012**, 36, 1874-82	6.7	259
120	PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. *Journal of Clinical Investigation*, **2018**, 128, 580-588	15.9	259
119	Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. *Clinical Cancer Research*, **2017**, 23, 124-136	12.9	258
118	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. *Cancer Immunology Research*, **2017**, 5, 417-424	12.5	241
117	Neoadjuvant checkpoint blockade for cancer immunotherapy. *Science*, **2020**, 367,	33.3	231
116	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2019**, 5, 1195-1204	13.4	224
115	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. *Human Pathology*, **2016**, 47, 52-63	3.7	214
114	Antagonists of PD-1 and PD-L1 in Cancer Treatment. *Seminars in Oncology*, **2015**, 42, 587-600	5.5	206
113	Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. *New England Journal of Medicine*, **2016**, 374, 896-8	59.2	191
112	Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. *Clinical Cancer Research*, **2008**, 14, 366-9	12.9	190
111	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. *Journal of Clinical Oncology*, **2019**, 37, 693-702	2.2	188
110	Implications of the tumor immune microenvironment for staging and therapeutics. *Modern Pathology*, **2018**, 31, 214-234	9.8	182
109	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. *Clinical Cancer Research*, **2015**, 21, 3969-76	12.9	172
108	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. *Journal of Clinical Oncology*, **2017**, 35, 2193-2202	2.2	159

107	Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). *Annals of Oncology*, **2018**, 29, 1853-1860	10.3	153
106	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. *Cancer Research*, **2019**, 79, 1214-1225	10.1	117
105	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E7769-E7777	11.5	116
104	B7-H5 costimulates human T cells via CD28H. *Nature Communications*, **2013**, 4, 2043	17.4	111
103	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. *Laboratory Investigation*, **2017**, 97, 1063-1071	5.9	105
102	The immune microenvironment of breast ductal carcinoma in situ. *Modern Pathology*, **2016**, 29, 249-58	9.8	98
101	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. *OncoImmunology*, **2016**, 5, e1134412	7.2	94
100	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. *Clinical Cancer Research*, **2017**, 23, 4938-4944	12.9	90
99	Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. *Urology*, **2015**, 85, 703.e1-6	1.6	88
98	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncology, The*, **2019**, 20, e378-e389	21.7	88
97	Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).. *Journal of Clinical Oncology*, **2013**, 31, 3016-3016	2.2	88
96	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade **2017**, 5, 23		87
95	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. *Cancer Immunology Research*, **2016**, 4, 726-33	12.5	85
94	Keratin-dependent regulation of Aire and gene expression in skin tumor keratinocytes. *Nature Genetics*, **2015**, 47, 933-8	36.3	77
93	Photoactivated composite biomaterial for soft tissue restoration in rodents and in humans. *Science Translational Medicine*, **2011**, 3, 93ra67	17.5	77
92	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. *Clinical Cancer Research*, **2017**, 23, 7333-7339	12.9	76
91	PEG hydrogel degradation and the role of the surrounding tissue environment. *Journal of Tissue Engineering and Regenerative Medicine*, **2015**, 9, 315-8	4.4	73
90	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 1818-1831	8.9	73

89	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab **2018**, 6, 99		73
88	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. *Journal of Clinical Oncology*, **2020**, 38, 2476-2487	2.2	72
87	Merkel cell carcinoma: update and review. *Seminars in Cutaneous Medicine and Surgery*, **2011**, 30, 48-56	1.4	68
86	PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy. *Cancer Journal (Sudbury, Mass)*, **2018**, 24, 41-46	2.2	65
85	Interleukin-36□producing macrophages drive IL-17-mediated fibrosis. *Science Immunology*, **2019**, 4,	28	64
84	Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. *International Journal of Cancer*, **2018**, 143, 3201-3208	7.5	64
83	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. *Clinical Cancer Research*, **2020**, 26, 4268-4279	12.9	59
82	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.. *New England Journal of Medicine*, **2022**,	59.2	59
81	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. *Journal of Translational Medicine*, **2015**, 13, 214	8.5	58
80	Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. *Journal of the American Academy of Dermatology*, **2012**, 67, 717-26	4.5	55
79	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation **2020**, 8,		54
78	Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. *Head and Neck*, **2015**, 37, 1088-95	4.2	54
77	Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. *OncoImmunology*, **2014**, 3, e963413	7.2	52
76	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. *Clinical Cancer Research*, **2017**, 23, 3168-3180	12.9	51
75	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 T-cell Function. *Cancer Immunology Research*, **2019**, 7, 257-268	12.5	51
74	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. *JAMA Oncology*, **2017**, 3, 974-978	13.4	49
73	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. *Clinical Cancer Research*, **2016**, 22, 1161-72	12.9	49
72	Secretory Carcinoma of the Skin Harboring ETV6 Gene Fusions: A Cutaneous Analogue to Secretory Carcinomas of the Breast and Salivary Glands. *American Journal of Surgical Pathology*, **2017**, 41, 62-66	6.7	47

71	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2020**, 26, 1327-1337	12.9	46
70	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. *American Journal of Surgical Pathology*, **2017**, 41, 1381-1389	6.7	44
69	PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. *Cancer Immunology Research*, **2015**, 3, 110-5	12.5	43
68	A novel role for CD36 in VLDL-enhanced platelet activation. *Diabetes*, **2003**, 52, 1248-55	0.9	43
67	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. *Clinical Cancer Research*, **2020**, 26, 545-551	12.9	43
66	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. *Journal of Neuro-Oncology*, **2015**, 121, 251-9	4.8	42
65	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer **2020**, 8,		40
64	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. *Nature*, **2021**, 596, 126-132	50.4	40
63	Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. *Journal of Molecular Diagnostics*, **2010**, 12, 320-7	5.1	39
62	A broad survey of cathepsin K immunoreactivity in human neoplasms. *American Journal of Clinical Pathology*, **2013**, 139, 151-9	1.9	38
61	Benign nodal nevi frequently harbor the activating V600E BRAF mutation. *American Journal of Surgical Pathology*, **2009**, 33, 568-71	6.7	35
60	Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. *Clinical Cancer Research*, **2007**, 13, 4331-5	12.9	33
59	PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. *Journal of Cutaneous Pathology*, **2010**, 37, 938-43	1.7	32
58	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. *Modern Pathology*, **2017**, 30, 1551-1560	9.8	30
57	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. *Clinical Cancer Research*, **2019**, 25, 5250-5259	12.9	29
56	Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. *Journal of Cutaneous Pathology*, **2011**, 38, 775-9	1.7	28
55	Impact of elastic staining on the staging of peripheral lung cancers. *American Journal of Surgical Pathology*, **2007**, 31, 953-6	6.7	28
54	HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma. *American Journal of Surgical Pathology*, **2014**, 38, 426-32	6.7	26

53	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. *Ca-A Cancer Journal for Clinicians*, **2016**, 66, 408-36	220.7	26
52	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. *Science*, **2021**, 372,	33.3	25
51	Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. *Blood Advances*, **2017**, 1, 1324-1334	7.8	24
50	PD-L1 expression in medulloblastoma: an evaluation by subgroup. *Oncotarget*, **2018**, 9, 19177-19191	3.3	24
49	Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. *Journal of Visualized Experiments*, **2013**,	1.6	23
48	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial **2021**, 9,		23
47	Characterization of human mesenchymal stem cell-engineered cartilage: analysis of its ultrastructure, cell density and chondrocyte phenotype compared to native adult and fetal cartilage. *Cells Tissues Organs*, **2010**, 191, 12-20	2.1	22
46	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. *Breast Cancer Research*, **2019**, 21, 72	8.3	21
45	Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma. *OncoImmunology*, **2015**, 4, e1029704	7.2	21
44	Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations. *Journal of Cutaneous Pathology*, **2015**, 42, 807-14	1.7	21
43	Emerging immunologic biomarkers: setting the (TNM-immune) stage. *Clinical Cancer Research*, **2014** , 20, 2023-5	12.9	17
42	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. *Cell Reports Medicine*, **2020**, 1, 100139	18	17
41	Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors. *Frontiers in Oncology*, **2018**, 8, 649	5.3	17
40	Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma. *Journal of Cutaneous Pathology*, **2014**, 41, 928-35	1.7	15
39	Langerhans cell density and high-grade vulvar intraepithelial neoplasia in women with human immunodeficiency virus infection. *Journal of Cutaneous Pathology*, **2007**, 34, 565-70	1.7	12
38	Pleuropulmonary blastoma: cytogenetic and spectral karyotype analysis. *Pediatric and Developmental Pathology*, **2006**, 9, 453-61	2.2	12
37	To Control Site-Specific Skin Gene Expression, Autocrine Mimics Paracrine Canonical Wnt Signaling and Is Activated Ectopically in Skin Disease. *American Journal of Pathology*, **2016**, 186, 1140-50	5.8	12
36	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. *Cancer Immunology Research* , **2019**, 7, 805-812	12.5	9

35	PD-L1 expression in inflammatory myofibroblastic tumors. *Modern Pathology*, **2018**, 31, 1155-1163	9.8	9
34	ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry. *Journal of Thoracic Oncology*, **2016**, 11, S249	8.9	9
33	Myofibroma, Myopericytoma, Myoepithelioma, and Myofibroblastoma of Skin and Soft Tissue. *Surgical Pathology Clinics*, **2011**, 4, 745-59	3.9	9
32	Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. *World Neurosurgery*, **2020**, 135, e187-e193	2.1	8
31	Increased Expression of PD-1 and PD-L1 in Patients With Laryngotracheal Stenosis. *Laryngoscope*, **2021**, 131, 967-974	3.6	8
30	Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. *Melanoma Research*, **2017**, 27, 85-96	3.3	7
29	Differentiated (simplex) vulvar intraepithelial neoplasia: a case report and review of the literature. *American Journal of Dermatopathology*, **2011**, 33, e27-30	0.9	7
28	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. *Journal of Clinical Oncology*, **2012**, 30, CRA2509-CRA2509	2.2	7
27	Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. *Cancer Immunology, Immunotherapy*, **2021**, 70, 1227-1237	7.4	7
26	Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study **2021**, 9,		7
25	New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy		6
24	Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparation. *Diagnostic Cytopathology*, **2010**, 38, 555-63	1.4	5
23	Dermal and Subcutaneous Plexiform Soft Tissue Neoplasms. *Surgical Pathology Clinics*, **2011**, 4, 819-42	3.9	4
22	New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy.. *Patterns*, **2021**, 2, 100372	5.1	4
21	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. *European Urology Oncology*, **2021**,	6.7	4
20	Plaque-like syringoma with involvement of deep reticular dermis. *Journal of the American Academy of Dermatology*, **2014**, 71, e206-7	4.5	3
19	Abstract 6584: The AstroPath platform for spatially resolved, single cell analysis of the tumor microenvironment (TME) using multispectral immunofluorescence (mIF) **2020**,		3
18	PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors. *Cureus*, **2019**, 11, e6352	1.2	3

17	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. *Clinical Cancer Research*, **2021**, 27, 394-401	12.9	3
16	PD-L1 and Other Immunological Diagnosis Tools **2018**, 371-385		2
15	Follicular Mucinosis in a Male Adolescent with a History of Acute Myelogenous Leukemia and Graft-versus-Host Disease. *Pediatric Dermatology*, **2016**, 33, e34-5	1.9	2
14	Haemophilus influenzae serotype f purulent pericarditis: a cause of death in a child with Down syndrome. *Diagnostic Microbiology and Infectious Disease*, **2006**, 56, 87-9	2.9	2
13	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. *Journal of Clinical Oncology*, **2012**, 30, CRA2509-CRA2509	2.2	2
12	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). *Journal of Translational Medicine*, **2020**, 18, 346	8.5	2
11	Quantitative Assessment of the Immune Microenvironment in Patients With Iatrogenic Laryngotracheal Stenosis. *Otolaryngology - Head and Neck Surgery*, **2021**, 164, 1257-1264	5.5	2
10	Poliosis Circumscripta: A Mark of Melanoma. *American Journal of Medicine*, **2019**, 132, 1417-1418	2.4	1
9	Multifocal ischemic necroses of varying age (MINOVA): A distinctive form of atherosclerotic heart disease. *Pathology Research and Practice*, **2008**, 204, 113-20	3.4	1
8	Adaptive immune resistance in gastro-esophageal cancer: Correlating tumoral/stromal PDL1 expression with CD8+ cell count.. *Journal of Clinical Oncology*, **2015**, 33, 4031-4031	2.2	1
7	PDL1 status in muscle-invasive urothelial carcinoma in the context of neoadjuvant cisplatin-based chemotherapy.. *Journal of Clinical Oncology*, **2015**, 33, 300-300	2.2	1
6	PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers.. *Journal of Clinical Oncology*, **2012**, 30, 5506-5506	2.2	1
5	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). *Journal of Translational Medicine*, **2021**, 19, 238	8.5	1
4	Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance **2021**, 9,		1
3	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. *Cancer Immunology Research*, **2021**, 9, 1262-1269	12.5	1
2	Safety and immunologic correlates of allogeneic melanoma GVAX (MelGVAX), a genetically engineered whole-cell melanoma vaccine.. *Journal of Clinical Oncology*, **2014**, 32, e20001-e20001	2.2	
1	Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply. *JAMA Oncology*, **2020**, 6, 299	13.4	